Par Pharma Buys Three Drugs From Teva

October 2011
Mergers & Acquisitions Report;10/24/2011, Vol. 24 Issue 43, p4
The article reports on Teva Pharmaceuticals' sale of the rights to three of its drug products to Par Pharmaceutical Cos. Inc.to avoid conflict related to its acquisition of Cephalon. Terms of the agreement transfer Abbreviated New Drug Applications (ANDAs) for fentanyl citrate lozenges, cyclobenzaprine ER capsules, and the U.S. rights to sell modafinil tablets. The requirement for Teva to divest its interests in making generics for Cephalon drugs is addressed.


Related Articles

  • GENERICS NEWSLINE.  // MPR - Pharmacist's Edition;Summer2012, Vol. 6 Issue 2, pA.8 

    The article offers brief information on generic drugs. Teva Pharmaceuticals Srl has launched its Escitalopram tablets which is the generic version of Forest Laboratories Inc.'s Lexapro. Watson Pharmaceuticals Inc. has unveiled its Metformin hydrochloride extended-release tablets which is the...

  • Kirkland helps Teva win bid battle for Cephalon. Hollander, Gavriel // Lawyer;5/9/2011, Vol. 25 Issue 19, p11 

    The article reports that Kirklind & Ellis and Skadden Arps Slate Meagher & Horn have helped pharmaceutical company Teva to acquire biopharmaceutical firm Cephalon.

  • TPG to Buy Generic Drugmaker Par Pharma for $1.9 Billion.  // MondayMorning;7/23/2012, Vol. 20 Issue 29, p1 

    The article reports on the plan of TPG Capital LP to acquire Par Pharmaceutical Cos. Inc. for $1.9 billion.

  • Par Agrees to Acquire JHP.  // Chain Drug Review;2/17/2014, Vol. 36 Issue 4, p48 

    The article informs that Par Pharmaceutical Cos. is acquiring JHP Group Holdings, the parent company of JHP Pharmaceuticals, headquartered in New Jersey, a pharmaceutical company that develops, manufactures and markets generic sterile injectable products.

  • Par Finishes Anchen Buy in Advance of Generic Wave. Reed, Vita // Orange County Business Journal;11/28/2011, Vol. 34 Issue 48, p50 

    The article reports on the acquisition of Irvine, California-based generic drug maker Anchen Pharmaceuticals Inc. by Woodcliff Lake, New Jersey-based Par Pharmaceutical Cos. Inc. in a 410 million dollar deal.

  • Par Purchasing Specialty Rx Firm.  // Chain Drug Review;9/26/2011, Vol. 33 Issue 16, p66 

    The article reports on the acquisition of Anchen Pharmaceuticals Inc., a pharmaceutical company that develops commercialized and generic products by the Par Pharmaceutical Cos. Inc.

  • Par and Orchid Form Generics Alliance.  // Chemical Market Reporter;5/31/2004, Vol. 265 Issue 22, p3 

    Reports that generic drug company Par Pharmaceutical Inc. has formed an alliance with Chennai, India-based Orchid Chemicals and Pharmaceuticals Ltd. to develop and market generic drugs. Development of various dosage forms of as many as seven cephalosporin antibiotics; Orchid's responsibility in...

  • Par Pharmaceutical Companies, Inc. SWOT Analysis.  // Pharmaceutical Resources, Inc. SWOT Analysis;Oct2012, p1 

    A business analysis of Par Pharmaceutical Cos. Inc., a specialty pharmaceutical company that produces, markers and distributes generic drugs and proprietary products, is provided, focusing on its strengths, weaknesses, opportunities for improvement and threats to the company. Strengths include...

  • Anchen Pharmaceuticals Set for $410 Million Sale to Par. Reed, Vita // Orange County Business Journal;8/29/2011, Vol. 34 Issue 35, p8 

    The article reports on the acquisition of Par Pharmaceutical Cos. Inc. in Woodcliff Lake, New Jersey by drug maker Anchen Pharmaceuticals Inc. in Irvine, California for 410 million dollars to expand Par's generic drug offerings.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics